StockData
ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Artiva Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.89+0.04 (+0.68%)

Close on Oct 19, 2026

Market cap
$232.14M
P/E (TTM)
–
Dividend yield
–

Artiva Biotherapeutics, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Artiva Biotherapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.